A new drug for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis:avacopan
Avacopan is an oral selective complement C5a receptor(C5aR)inhibitor that was approved by the FDA in October 2021 for the treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis in combination with standard therapy(glucocorticoids).Clinical studies have shown that avacopan can significantly reduce the dose of glucocorticoids used in the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis,reduce corticosteroid-related toxicity,and improve the prognosis of the disease.This article summarizes the mechanism of action,pharmacokinetics,clinical studies and safety of avacopan,aiming to provide references for clinical application.
NETL
NSTL
万方数据
